Amgen MariTide Switch Trial Continues Enrollment as Obesity Market Positions for 2027-2028 Monthly Injectable Launch
Amgen (NASDAQ: AMGN) continued enrollment through September 2026 in the dedicated MARITIME switch trial that specifically tests whether patients currently on weekly semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can be converted to monthly MariTide (maridebart cafraglutide, antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism) with equivalent weight-loss maintenance and comparable tolerability. Filing for FDA approval is planned late 2026 to early 2027 with anticipated launch 2027-2028. Six total Phase 3 MariTide trials are enrolling across obesity (MARITIME-1), obesity plus type 2 diabetes (MARITIME-2), cardiovascular outcomes (MARITIME-CVD), heart failure (MARITIME-HF), obstructive sleep apnea (MARITIME-OSA), plus the switch trial. Cantor Fitzgerald analyst commentary earlier in 2026 had flagged a 4% bone mineral density decline signal from Phase 1 as a factor to watch; Phase 3 data on bone health will affect prescribing guidance especially for adults over 60 or with prior fracture history.